Residency · Residency · Preventive Medicine

Substance Use Disorders: Prevention and Harm Reduction

Overview

Substance use disorders (SUDs) affect ~48 million Americans (17% of adults >=12) Drug overdose deaths reached ~107,000 in 2023, driven primarily by synthetic opioids (fentanyl) Alcohol causes ~178,000 deaths/year in the U.S. (third leading preventable cause of death) SUDs are chronic, relapsing brain diseases with genetic, environmental, and neurobiological components. Harm reduction strategies accept that substance use occurs and aim to reduce associated harms without requiring abstinence. Preventive medicine integrates population-level prevention, clinical screening, and policy advocacy.

The Opioid Crisis

Epidemiology

Three waves: (1) prescription opioids (~1990s-2010), (2) heroin (~2010-2013), (3) synthetic opioids/fentanyl (~2013-present) Illicitly manufactured fentanyl now present in ~90% of opioid overdose deaths. Xylazine ("tranq"): veterinary sedative increasingly found in fentanyl supply; causes necrotic skin ulcers; not reversed by naloxone. Highest overdose rates: American Indian/Alaska Native, non-Hispanic White, and non-Hispanic Black populations. Polysubstance use: rising stimulant-opioid co-involvement (fentanyl + methamphetamine, fentanyl + cocaine)

Prescription Opioid Prevention

CDC Clinical Practice Guideline for Prescribing Opioids (2022): replaces 2016 guideline. Nonopioid therapies preferred for chronic pain. When opioids are used: start with lowest effective dose, immediate-release formulations, short duration. Avoid exceeding 90 MME/day without careful reassessment. Co-prescribe naloxone when risk factors present. Prescription Drug Monitoring Programs (PDMPs): state-run databases tracking controlled substance prescriptions; mandatory use reduces doctor-shopping and inappropriate prescribing. Safe storage and disposal: medication take-back programs, drug deactivation pouches, lock boxes.

Naloxone Distribution

Naloxone (Narcan): opioid antagonist that reverses respiratory depression. Available OTC (nasal spray, 4 mg) since 2023 (FDA approval for non-prescription status) Community distribution programs: pharmacies, harm reduction organizations, first responders, bystanders. Standing order laws: allow pharmacists to dispense naloxone without individual prescription. Evidence: community naloxone distribution reduces overdose mortality by 11-46%. Limitations: shorter half-life than fentanyl; multiple doses often needed; does not reverse xylazine effects.

Alcohol Use Disorder

Epidemiology

~29 million Americans meet criteria for AUD; only ~7% receive treatment. Alcohol-attributable deaths: ~178,000/year (50% from chronic conditions, 50% from acute events) Excessive alcohol use includes binge drinking (>=4 drinks for women, >=5 for men on an occasion) and heavy drinking. Binge drinking prevalence: ~25% of adults; highest in ages 18-34. COVID-19 pandemic associated with significant increases in alcohol consumption and AUD.

Policy Interventions

Taxation: most effective policy; every 10% price increase reduces consumption by ~5-7%. Minimum legal drinking age (21): prevents ~900 traffic deaths/year; one of the most successful public health laws. Drunk driving laws: 0.08 BAC limit, sobriety checkpoints, ignition interlock devices. Outlet density regulation: limiting alcohol retailer density associated with reduced consumption and violence. Marketing restrictions: self-regulation has been largely ineffective; children/adolescents widely exposed. Minimum unit pricing: Scotland, Ireland, Australia -- sets floor price per unit of alcohol; reduces heavy drinking.

Screening and Brief Intervention

SBIRT (Screening, Brief Intervention, and Referral to Treatment)

Evidence-based approach for identifying and addressing substance use in clinical settings. Screening: validated tools -- AUDIT-C (alcohol), DAST-10 (drugs), single-question screeners, NIDA Quick Screen. Brief Intervention: 5-15 minute motivational counseling session; reduces unhealthy alcohol use by 20-25%. Referral to Treatment: for those with moderate-severe SUD. USPSTF: screen all adults >=18 for unhealthy alcohol use (B recommendation); insufficient evidence for illicit drug screening in general population.

CAGE, AUDIT, AUDIT-C

CAGE: 4 questions (Cut down, Annoyed, Guilty, Eye-opener); >=2 positive suggests AUD; high specificity. AUDIT: 10-item tool; gold standard for hazardous drinking identification; score >=8 suggests hazardous use. AUDIT-C: 3-item consumption subset of AUDIT; >=4 in men, >=3 in women suggests unhealthy use.

Harm Reduction Strategies

Supervised Consumption Sites (SCS)

Facilities where individuals use pre-obtained drugs under medical supervision. Services: sterile supplies, naloxone availability, medical monitoring, linkage to treatment. >120 SCS globally (Canada, Europe, Australia); first authorized U.S. site: OnPoint NYC (2021) Evidence from Insite (Vancouver): 35% reduction in overdose deaths in surrounding area; increased treatment uptake; no increase in crime or drug use initiation. No reported overdose death has occurred inside an SCS. Controversial: opponents argue they enable drug use; legal barriers in most U.S. jurisdictions.

Syringe Services Programs (SSPs)

Provide sterile injection equipment, naloxone, wound care, testing (HIV, HCV), and treatment referral. Reduce HIV transmission by ~50% and HCV transmission significantly. Associated with increased entry into substance use treatment (5x more likely to enter treatment) Legal in most states; some have restrictive laws or local opposition. CDC and SAMHSA endorse SSPs as evidence-based prevention.

Medication for Opioid Use Disorder (MOUD)

Methadone: full mu-opioid agonist; dispensed through licensed OTPs; reduces overdose mortality by 50-75%. Buprenorphine (Suboxone): partial agonist; office-based prescribing (X-waiver requirement eliminated 2023); reduces mortality by ~50%. Naltrexone (Vivitrol): opioid antagonist; monthly injection; no abuse potential; requires full opioid detoxification first. MOUD is the standard of care for OUD -- "medication-assisted treatment" terminology being replaced by "medication for opioid use disorder" to destigmatize. Barriers: limited OTP access (especially rural), stigma among patients and providers, prior authorization requirements.

Other Harm Reduction Tools

Drug checking services (fentanyl test strips): allow users to detect fentanyl contamination. Managed alcohol programs: for individuals with severe AUD and homelessness. Safer supply programs (Canada): prescribed pharmaceutical alternatives to toxic illicit supply.

<image>A three-panel timeline showing the three waves of the U.S. opioid crisis: Wave 1 (1990s-2010) showing rising prescription opioid deaths with an icon of a prescription bottle, Wave 2 (2010-2013) showing heroin deaths with a syringe icon, and Wave 3 (2013-present) showing synthetic opioid/fentanyl deaths with a powder icon. Overlaid line graphs show death rates for each substance category over time, with the fentanyl line showing the steepest rise. A fourth emerging trend line shows xylazine co-involvement. Opioid crisis education illustration.</image>

<image>A flowchart showing the SBIRT (Screening, Brief Intervention, and Referral to Treatment) clinical pathway. Starting with universal screening (AUDIT-C for alcohol, NIDA Quick Screen for drugs), branching into low risk (positive feedback), risky/hazardous use (brief intervention with motivational interviewing), and moderate-severe SUD (referral to specialty treatment). Each branch includes specific actions, time requirements, and evidence for effectiveness. SBIRT education illustration.</image>

<image>An infographic comparing the three FDA-approved medications for opioid use disorder: methadone (full agonist, OTP dispensing, reduces mortality 50-75%), buprenorphine (partial agonist, office-based prescribing, reduces mortality ~50%), and naltrexone (antagonist, monthly injection, requires detox first). Each medication shows mechanism, setting, key advantages, key limitations, and mortality reduction data. MOUD education illustration.</image>

Clinical Pearls

All three FDA-approved medications for OUD reduce overdose mortality -- withholding MOUD is not evidence-based; abstinence-only approaches have higher mortality rates. The X-waiver requirement for buprenorphine prescribing was eliminated in 2023 -- any provider with a DEA license can now prescribe buprenorphine for OUD. Brief intervention for unhealthy alcohol use in primary care reduces consumption by 20-25% -- a highly efficient use of clinical time (5-15 minutes) Fentanyl test strips are a low-cost, evidence-based harm reduction tool but remain classified as drug paraphernalia in some states. For boards: know the three waves of the opioid crisis, SBIRT components, AUDIT-C cutoffs, MOUD agents and their mechanisms, and the evidence for syringe services programs and naloxone distribution.

References

• CDC. Clinical Practice Guideline for Prescribing Opioids for Pain. MMWR. 2022;71(RR-3):1-95.
• Jonas DE, et al. Screening for unhealthy alcohol use. JAMA. 2023;329(20):1788-1797.
• Marshall BDL, et al. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility (Insite). Lancet. 2011;377(9775):1429-1437.
• Mattick RP, et al. Buprenorphine maintenance versus placebo for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
• USPSTF. Screening for unhealthy drug use. JAMA. 2020;323(22):2301-2309.

Read this lecture as Markdown